FIELD: medicine.
SUBSTANCE: invention relates to the use of an inhibitor of T-cell co-stimulation and/or activation for the treatment or prevention of heart failure induced by pressure overload. The specified inhibitor contains an extracellular domain CTLA4 or its functional derivative, which binds CD80 and/or CD86. The use of a nucleic acid molecule encoding the specified inhibitor, an expression vector containing nucleic acid, a genetically constructed host cell, which expresses the specified inhibitor, a pharmaceutical composition containing the specified inhibitor or a nucleic acid molecule, or a vector or a host cell for the treatment or prevention of heart failure induced by pressure overload is also proposed.
EFFECT: specified inhibitor, nucleic acid molecule, vector, host cell, and pharmaceutical composition are used in a method for the treatment or prevention of heart failure induced by pressure overload and a method for the treatment or prevention of heart hypertrophy induced by pressure overload and fibrosis.
21 cl, 16 dwg, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
| AMHRII BINDING COMPOUNDS FOR THE PREVENTION OR TREATMENT OF LUNG CANCERS | 2018 |
|
RU2797506C2 |
| ANTIBODIES, THEIR APPLICATION AND METHODS OF APPLICATION | 2016 |
|
RU2725221C2 |
| CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR | 2018 |
|
RU2805232C2 |
| ANTI-AGE ANTIBODIES FOR TREATING INFLAMMATION AND AUTOIMMUNE DISORDERS | 2015 |
|
RU2721568C2 |
| NOVEL ANTI-PD-1 ANTIBODIES | 2016 |
|
RU2729830C2 |
| AMHRII BINDING COMPOUNDS FOR PREVENTING OR TREATING CANCER | 2018 |
|
RU2816523C2 |
| FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN AND ITS USE | 2019 |
|
RU2811541C2 |
| COMPOSITIONS AND METHODS FOR TREATING TYPE 1 DIABETES | 2017 |
|
RU2760997C2 |
| COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX CONTAINING A CELL-PENETRATING PEPTIDE, A CARGO MOLECULE, AND A TLR PEPTIDE AGONIST, FOR APPLICATION IN MEDICINE | 2017 |
|
RU2769314C1 |
